Monopar Therapeutics (NASDAQ:MNPR) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Monopar Therapeutics (NASDAQ:MNPR) from a hold rating to a sell rating in a research note released on Sunday morning.

Several other brokerages have also commented on MNPR. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $109.00 to $119.00 in a report on Thursday. BTIG Research upped their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Barclays reissued an “overweight” rating and set a $128.00 target price (up from $125.00) on shares of Monopar Therapeutics in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $117.42.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR opened at $113.04 on Friday. The stock has a market cap of $758.50 million, a price-to-earnings ratio of -52.09 and a beta of 1.47. The business has a 50 day simple moving average of $96.11 and a 200 day simple moving average of $71.53. Monopar Therapeutics has a 52 week low of $29.18 and a 52 week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. On average, analysts predict that Monopar Therapeutics will post -2.96 EPS for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics in the first quarter worth $673,000. Jane Street Group LLC acquired a new position in Monopar Therapeutics in the 1st quarter valued at $377,000. Geode Capital Management LLC grew its stake in Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after buying an additional 48,379 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. Finally, Rhumbline Advisers acquired a new position in Monopar Therapeutics during the 2nd quarter worth $209,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics News Roundup

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $125 price target, modestly above the recent trading level. Its published forecasts anticipate a transition from losses to positive earnings by FY2028, with additional long-term estimates extending into FY2029. What is HC Wainwright’s Forecast for MNPR FY2029 Earnings?
• Neutral Sentiment: Analyst coverage highlighted Monopar among healthcare companies, but the supplied report does not identify a new price target or specific fundamental catalyst. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across FY2026 through FY2028: FY2026 to a loss of $3.07 per share, FY2027 to a loss of $1.46, and FY2028 earnings to $0.87. Quarterly estimates were also lowered, including Q3 2026 to a loss of $0.90 and Q4 2026 to a loss of $1.08, signaling expectations for weaker near-term profitability.
• Negative Sentiment: Zacks Research downgraded Monopar from “Strong Buy” to “Hold,” while Wall Street Zen lowered the stock to “Sell.” These rating changes may weigh on sentiment, particularly after the stock’s strong run and elevated valuation. Monopar Therapeutics Lowered to Sell Rating

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.